NOVELIX (NOVELIX) | Stock Overview & Key Data
NOVELIX Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹88.40 on June 15, 2026
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NOVELIX
NOVELIX
|
1.16B Small-cap | 23.32% | 61.28% | 62.04% | 40.58% | 41.58% | 181.69% | 242.11% | 242.11% | 242.11% | 242.11% | 242.11% |
|
Entero Healthcare
ENTERO
|
54.69B Mid-cap | 0.29% | -5.86% | 12.11% | 12.06% | -0.64% | -4.75% | -1.12% | -1.12% | -1.12% | -1.12% | -1.12% |
|
Royal Sense
ROYAL
|
924.51M Small-cap | 0.93% | -22.86% | -30.37% | -49.77% | -40.28% | -59.36% | -8.50% | -8.50% | -8.50% | -8.50% | -8.50% |
|
Amwill Health Care
AMWILL
|
669.92M Small-cap | 17.21% | 42.72% | 37.61% | 22.87% | -4.99% | -39.04% | -57.48% | -57.48% | -57.48% | -57.48% | -57.48% |
|
Trimurthi
TRIMURTHI
|
500.39M Small-cap | 23.32% | 61.28% | 62.04% | 40.58% | 41.58% | 169.35% | 768.13% | 774.86% | 1,174.19% | 381.71% | 381.71% |
|
Welcure Drugs
WELCURE
|
370.78M Small-cap | 0.00% | -10.34% | -3.70% | -45.83% | -38.10% | -75.00% | -25.00% | 17.39% | -77.50% | 50.00% | -30.77% |
Ownership & Short Interest
Calculate Your NOVELIX Investment Returns
Long-Term Investment Performance Analysis
NOVELIX stock price in Dec 2024 was ₹24.15, A ₹1,000.00 lump sum investment in NOVELIX made 1 years ago would be worth approximately ₹3,556.11 today, representing a outstanding return of 255.61%. This translates to an annualized return (CAGR) of 138.93%.
1 Year 5 Months Investment Scenario (Dec 2024 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is NOVELIX's 52-week high and low?
- In the last 52 weeks, NOVELIX reached a high of ₹88.40 (on June 15, 2026) and a low of ₹29.33 (on June 23, 2025).
- What is the market cap and P/E ratio for NOVELIX?
- Curious about NOVELIX's size and valuation? Its market capitalization stands at 1.16B. When it comes to valuation, the P/E ratio (trailing twelve months) is 48.76, and the forward P/E (looking ahead) is N/A.
- Does NOVELIX pay dividends? If so, what's the yield?
- As for dividends, NOVELIX isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are NOVELIX's main competitors or similar companies to consider before investing?
When looking at NOVELIX, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Entero Healthcare
ENTERO54.69B Healthcare Medical Distribution -4.75% -1.12% Royal Sense
ROYAL924.51M Healthcare Medical Distribution -59.36% -8.50% Amwill Health Care
AMWILL669.92M Healthcare Medical Distribution -39.04% -57.48% Trimurthi
TRIMURTHI500.39M Healthcare Medical Distribution 169.35% 768.13% Welcure Drugs
WELCURE370.78M Healthcare Medical Distribution -75.00% -25.00% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for NOVELIX PHARMACEUTICALS LIMITE? (e.g., ROE, Debt/Equity)
- To get a sense of NOVELIX's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.48%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 3.21%.
- What is the recent revenue and earnings growth for NOVELIX?
- Looking at NOVELIX's growth, its revenue over the trailing twelve months (TTM) was INR1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 813.10%, and quarterly earnings saw a YoY growth of 579.10%.
- How much of NOVELIX stock is held by insiders and institutions?
- Wondering who owns NOVELIX stock? Company insiders (like executives and directors) hold about 70.63% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.